文献速递中医妇科中药与中成药合理使用

植物药代谢物育麟珠治疗神经障碍所致多囊卵巢综合征的系统评价与Meta分析

Plant medicine metabolite Yulinzhu treating neurological disorder causing polycystic ovary syndrome: a systematic review and a meta-analysis.
PubMed 文献 · Front Pharmacol · 2024-08-15

该系统评价与Meta分析检索PubMed、EMBASE、Cochrane Library及CNKI等数据库至2024年6月1日,纳入6项比较育麟珠与安慰剂、标准治疗或其他积极治疗的RCT,评价其治疗PCOS的疗效与机制。结果显示育麟珠可提高有效率(RR=1.19)、妊娠率(RR=2.80)和排卵率(RR=1.33),并改善黄体生成素、睾酮和雌二醇水平,但卵泡雌激素变化无统计学意义。

要点

  • 育麟珠可提高PCOS患者有效率、妊娠率和排卵率。
  • 育麟珠可降低LH和睾酮水平、升高雌二醇水平。
  • 卵泡雌激素变化无统计学意义,证据需更大样本验证。

核心结论

  • 植物药复方育麟珠可能通过激素调节、抗炎和神经保护作用有效治疗PCOS。
  • 期待更大规模、设计良好的临床试验进一步验证结论。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE、Cochrane Library和CNKI等数据库至2024年6月1日。
  • 筛选891条记录,最终纳入6项随机对照试验。
  • 纳入比较育麟珠与安慰剂、标准治疗或其他积极治疗PCOS患者的RCT。
  • 由两名评价者独立进行数据提取和质量评价,采用固定效应和随机效应模型,用I2统计量评估异质性。

主要发现

  • 有效率RR=1.19,95%CI(1.10,1.29),p<0.0001。
  • 妊娠率RR=2.80,95%CI(1.65,4.76),p<0.0001。
  • 排卵率RR=1.33,95%CI(1.10,1.62),p=0.04。
  • 卵泡雌激素WMD=0.69,95%CI(-0.39,1.78),p=0.21。
  • 黄体生成素WMD=-2.27,95%CI(-3.86,-0.67),p=0.005;睾酮WMD=-0.44,95%CI(-0.64,-0.25),p<0.0001;雌二醇WMD=16.20,95%CI(2.74,29.67),p<0.0001。

关键数值与推荐

  • 纳入研究为比较育麟珠与安慰剂、标准治疗或其他积极治疗的RCT。
  • Meta分析采用固定效应和随机效应模型,异质性用I2统计量评估。

临床怎么用

  • 对于PCOS患者,育麟珠可能作为改善有效率和妊娠率的治疗选择。
  • 育麟珠可能有助于调节LH、睾酮和雌二醇水平。
  • 临床应用需结合患者具体情况,并关注证据局限性。

局限性

  • 纳入研究数量较少(6项),样本量有限。
  • 需要更大规模、设计良好的临床试验验证结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that affects women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Emerging evidence indicates that neurological disorders play a significant role in the etiology of PCOS, highlighting the complex interplay between the central nervous system (CNS) and ovarian function. Yulinzhu, a traditional Chinese medicine (TCM) formulation, has been traditionally used to regulate menstrual cycles and improve fertility. This study aims to investigate the efficacy and mechanisms of Yulinzhu in treating PCOS induced by neurological disorders. METHODS: An extensive literature search was performed across electronic databases such as PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI), covering publications up to 1 June 2024. The review included randomized controlled trials (RCTs) that compared Yulin Zhu with placebo, standard care, or other active treatments in patients with PCOS. Two reviewers independently carried out data extraction and quality assessment. Meta-analyses were conducted using both fixed and random-effects models, with heterogeneity evaluated using the I2 statistic. RESULTS: We screened 891 records and included 6 studi es in the meta-analysis. The meta-analysis revealed that Yulinzhu about effective rate [RR = 1.19, 95% CI (1.10, 1.29), p < 0.0001], pregnancy rate [RR = 2.80, 95% CI (1.65, 4.76), p < 0.0001] and ovulation rate [RR = 1.33, 95% CI (1.10, 1.62), p = 0.04]. Meta-analysis shows the results of follicle estrogen [WMD = 0.69, 95% CI (-0.39, 1.78), p = 0.21], luteinizing hormone [WMD = -2.27, 95% CI (-3.86, -0.67), p = 0.005], testosterone [WMD = -0.44, 95% CI (-0.64, -0.25), p < 0.0001], estradiol [WMD = 16.20, 95% CI (2.74, 29.67), p < 0.0001]. CONCLUSION: This study demonstrates that plant medicine compund Yulinzhu may effectively treats PCOS including hormonal regulation, anti-inflammatory actions, and neuroprotection. We expect further research with larger, well-designed clinical trials to substantiate our conclusions.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Jiao B, Chen R, Chen S, et al. Plant medicine metabolite Yulinzhu treating neurological disorder causing polycystic ovary syndrome: a systematic review and a meta-analysis. Front Pharmacol. 2024. PMID: 39211785. doi:10.3389/fphar.2024.1458621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。